2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Pfizer alleges Novo Nordisk is attempting to "catch and kill" Metsera, a company Pfizer was in the process of acquiring, in ...

Duvakitug outperformed placebo at week 14 in endoscopic response and was well tolerated among patients with moderately to severely active Crohn’s disease, according to research presented at ACG Annual ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

The healthcare industry has proven to be a resilient place for investors to put cash to work over the years. If you are ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...

El ensayo clínico, que busca reclutar a 1000 pacientes con COVID persistente en todo el país, explorará cómo la autoadministración de tirzepatida, el agonista del GLP-1 de Eli Lilly comercializado ...

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.

New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...